Multi‐omics analyses reveal unexpected effects of PLCg2 deficiency in the brain

Plcg2 polymorphisms are associated with both reduced (P522R) and increased (M28L) risk of Alzheimer’s disease (AD). The normal function of phospholipase C‐gamma‐2 (PLCg2) protein is to catalyze the hydrolysis of the membrane phosphatidylinositol‐4,5‐bisphosphate (PIP2) to form diacylglycerol (DAG) and inositol trisphosphate (IP3), which subsequently feed into downstream signaling pathways involving protein kinase C (PKC) activation, lipid homeostasis, and calcium regulation. In the brain, Plcg2 is primarily expressed by microglia. The Plcg2 P522R protective variant is a functional hypermorph, while it is predicted that M28L is a loss‐of‐function variant. The specific consequences of PLCg2 loss of function in the brain are unknown. We predicted that reduction of PLCg2 would lead to disrupted PIP2 and DAG metabolism, and that these changes would be associated with decreased PKC and calcium signaling resulting in changes in microglia phenotype.